TBNHealthPolitics
Trump administration advances plan for peptide drugs favored by RFK Jr.
Publication: STAT
Author: Associated Press
Source published: 15/10/2026, 20:46:09 UTC
Briefing created: 16/10/2026, 07:17:16 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 16/10/2026, 05:21:25 UTC.
Briefings
The Trump administration submitted an interim access policy to the White House and Office of Management and Budget on October 15, 2026, permitting specialty pharmacies to produce certain peptides. These peptides are favored by Health Secretary Robert F. Kennedy Jr. and other wellness influencers, and the policy aims to address unregulated injections. The plan faces significant economic impact review from the OMB.
Key points
- On October 15, 2026, the Trump administration submitted an interim access policy to the White House and Office of Management and Budget permitting specialty pharmacies to produce certain peptides.
- The policy addresses unregulated injections favored by Health Secretary Robert F. Kennedy Jr. and other wellness influencers.
Context
This policy represents a shift in federal oversight for peptide injections, which are increasingly popular among health influencers and followers of Health Secretary Robert F. Kennedy Jr. The submission to the White House and Office of Management and Budget indicates a move toward regulatory approval for these unregulated injections.
Limitations
The evidence is limited to a single government website posting from October 15, 2026, which states the plan was sent for review. No specific dates for the policy's implementation, approval timeline, or economic impact data are provided in the source.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 16/10/2026, 07:17:16 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeiegtbjuvjpusc6gzg2tlzxmmona3obgd6qyeuemb27iblyo3bncxi